Company Profile
Genmab A/S, a biotechnology company develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL) Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy.
It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients.
Its portfolio also includes tisotumab vedotin for solid tumors, Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC), Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors, GEN1059, GEN1055, and GEN1057 for solid tumors, and GEN1286 for advanced solid tumors
DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis. Its portfolio also includes RYBREVANT for NSCLC, TECVAYLI and TALVEY for R/R MM, Kesimpta for Relapsing multiple sclerosis, and TEPEZZA for thyroid eye disease. It also is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer.
Its portfolio also includes Amlenetug for multiple system atrophy, Inclacumab for vaso-occulsive crises in sickle cell diseases, and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Medarex, Inc., Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Novo Nordisk A/S, and argenx. Incorporated in 1998, Genmab is headquartered in Copenhagen, Denmark.